Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2009
Date:11/6/2009

ent of obligations under capital leases (68) (66) (199) (138) Proceeds from issuance of long-term debt 2,549 - 2,549 - Transaction costs (8) - (362) (118) Proceeds from issuance of share capital 366 3 527 8 Issuance costs of share capital (35) - (35) - ------------------------------------------------------------------------- 2,804 (63) 2,480 (248) ------------------------------------------------------------------------- Foreign exchange (loss) gain on cash held in foreign currencies (581) (176) (1,258) 448 Net increase (decrease) in cash and cash equivalents during the period 269 (16,829) 6,155 (1,445) Cash and cash equivalents, beginning of period 14,259 32,557 8,373 17,173 ------------------------------------------------------------------------- Cash and cash equivalents, end of period 14,528 15,728 14,528 15,728 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Supplemental cash flow information: Interest paid 802 632 2,294 1,777 Income taxes received 128 224 216 267 ------------------------------------------------------------------------- -------------------------------------------------------------------------

SOURCE Labopharm Inc.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The short film “Color of ... in honor of a true 9/11 hero, Welles Remy Crowther. ... including the 24 hours of Nuremberg International Short Film Festival ... , Actress, screenwriter and director Luciana Lagana plays ... together with her husband, Gregory Graham - Graham ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... Assist Doctors and Parents in Prevention ... ... and,Discovery Health,s Continuing Medical Education (CME) program have teamed,up to launch ... physicians and healthcare professionals about,childhood obesity and the necessary steps to ...
... Incorporates Three Pharsight ... ... PHST ), a leading provider of software, strategic,consulting, and regulatory ... Cooperative Research and,Development Agreement (CRADA) with the Food and Drug Administration,s ...
... Dec. 11, 2007 Researchers at UT Southwestern ... form of Cushing syndrome, a metabolic disorder caused by ... , The study, appearing in the December issue of ... of surgical outcomes reported in patients with subclinical Cushing ...
... Dec. 10 The holiday season is a time ... high-calorie,goodies with the cold winter weather, and December can ... Operations VP at 24 Hour Fitness health,clubs, says adding ... stave,off extra "holiday" pounds., Listen to this report ...
... Scheduled for December 18, 2007, MISSION VIEJO, Calif., ... ), the parent company of the Ensign(TM) group of,skilled ... that it expects to issue its fiscal third,quarter 2007 ... 2007., Conference Call, A live webcast will ...
... unnecessarily because they wrongly believe that morphine and other opioids ... a last resort rather than seeing them as legitimate pain ... a study published online today (Tuesday 11 December) in the ... also say the belief that opioids hasten death is widely ...
Cached Medicine News:Health News:Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic 2Health News:Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic 3Health News:Kaiser Permanente and Discovery Health Team Up to Fight Childhood Obesity Epidemic 4Health News:FDA and Pharsight Continue to Collaborate Under CRADA 2Health News:FDA and Pharsight Continue to Collaborate Under CRADA 3Health News:FDA and Pharsight Continue to Collaborate Under CRADA 4Health News:UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy 2Health News:UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy 3Health News:The Ensign Group, Inc. to Announce Third Quarter 2007 Financial Results 2Health News:Morphine: a comfort measure for the dying or pain control for the living? 2Health News:Morphine: a comfort measure for the dying or pain control for the living? 3Health News:Morphine: a comfort measure for the dying or pain control for the living? 4
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Decision Resources, one of the world,s leading research ... that, through 2019, an expanding aging population and increases ... percent annual growth in the chronic obstructive pulmonary disease ... findings from the topic entitled Chronic Obstructive Pulmonary ...
... -- DALLAS, Texas, August 31, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 2The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 3The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 4The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 5The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 6The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 7The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 8The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports 9
... Lyphochek Immunoassay Plus Control provides the ... control in the world for monitoring ... eliminating the need for separate controls. ... added preservatives, it is suitable for ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
... The Vidiera NsD Nucleic Sample Detection Platform ... post amplification. The new platform for ... capillary electrophoresis (CE), with software features that ... flexibility. Vidiera NsD has the capacity ...
... Sample Preparation Platform provides flexible, automated extraction ... can prepare up to 96 patient samples ... one half-hours, and performs onboard quantitation and ... minutes each. Based on Beckman Coulters ...
Medicine Products: